3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Phase 1
1
Status
Completed
4
Terminated
1
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
4
Sponsor
Cancer Type
CNS
4
Sarcoma
3
Conditions
Gliosarcoma
3
Glioblastoma
3
Neoplasms
2
Glioma
2
Brain Neoplasms
2
Recurrence
1
Interventions
Cyclophosphamide
1492
Cisplatin
1414
Paclitaxel
1317
Radiotherapy
1261
Carboplatin
1250
Gemcitabine
1215
Docetaxel
1109
Bevacizumab
1030
Fluorouracil
894
Doxorubicin
792
Dexamethasone
748
Rituximab
719
Capecitabine
716
Oxaliplatin
700
pembrolizumab
680
Etoposide
678
Irinotecan
634
Filgrastim
621
Cytarabine
586
Leucovorin
579
Nivolumab
558
Vincristine
515
Prednisone
475
Cetuximab
465
Bortezomib
459
Erlotinib Hydrochloride
456
Trastuzumab
447
Methotrexate
438
Lenalidomide
427
Pemetrexed
420
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Completed
×
Interventional
×
rindopepimut
×
Clear all
NCT01498328
2020-02-17
ReACT
Celldex Therapeutics
Phase 2
Completed
127 enrolled
NCT00458601
2018-01-16
ACT III
Celldex Therapeutics
Phase 2
Completed
82 enrolled
NCT01480479
2018-01-16
ACT IV
Celldex Therapeutics
Phase 3
Completed
745 enrolled
NCT00626015
2016-01-21
ZAP IT
Duke University
Phase 1
Completed
16 enrolled